2 assets in Endometrial Transitional Cell Carcinoma

Therapeutic assets addressing Endometrial Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Endometrial Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Endometrial Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)